State-of-the-Art Management for the Patient with Castration-Resistant Prostate Cancer in 2012.

Overview:Much progress has been made in metastatic castration-resistant prostate cancer (CRPC), and multiple new U.S. Food and Drug Administration (FDA)-approved survival-prolonging drugs are now a...